

RESPONSE

I. Status of the Claims

Claim 6 has been cancelled without prejudice or disclaimer as being drawn to a non-elected invention. Claim 7 has been amended. Claims 2-5 and 7-11 are therefore presently pending in the case. In an attempt to comply with the revised 37 C.F.R. §1.121 and for the convenience of the Examiner the status of the claims is described hereto as **Exhibit A**.

II. Support for the Amended Specification and Claims

Claim 7 has been amended in response to an objection and to further clarify the claim. Amendment of Claim 7 finds support throughout the specification as originally filed with particular support being provided by the original Claim 1 and the Sequence Listing as originally filed.

As the amendments of Claim 7 is fully supported by the specification and claims as originally filed, they do not constitute new matter. Entry therefore is respectfully requested.

III. Rejection of Claims 2-5 and 7-11 Under 35 U.S.C. § 101

The Action first rejects claims 2-5 and 7-11 under 35 U.S.C. § 101 because the claimed invention lacks patentable utility allegedly because the claimed invention is not supported by either a specific and substantial utility or a well established utility.

The Action recognizes that specification describes metalloproteinases (especially zinc metalloproteases of the ADAMTS family) indicates that the sequences of the present invention encode a metalloprotease (in particular ADAMSTS14).

In support of this recognized assertion, Applicants respectfully submit that SEQ ID NO:20 of the present invention is nearly identical to a sequence that is present in the leading scientific repository for biological sequence data (GENBANK). This sequence, GENBANK Accession No. Q8WXS8 (information provided as **Exhibit B**) has been annotated by third party scientists *wholly unaffiliated with Applicants* as "ADAMTS-14 precursor (A disintegrin and metalloproteinase with thrombospondin motifs 14) (ADAM-TS 14)". Thus Applicants' assertion that the sequences of the

present invention represent a variant of Q8WXS8 is supported by the evidence provided in **Exhibit C**, which contains an amino acid sequence comparison between SEQ ID NO:20 and the amino acid sequence of Q8WXS8. From this comparison, it can be seen that SEQ ID NO:20 shares a greater than 95% homology with the amino acid sequence of Q8WXS8.

Tissues which express the sequences of the present invention were described in the specification (page 3, line 5) as being human spinal cord, lymph node, bone marrow, trachea, mammary gland, skeletal muscle, pericardium, adipose, esophagus, bladder, fetal kidney, and fetal lung cells. The activity of the protein encoded by the sequences of the present invention is described in several publications (Abstracts provided as **Exhibit D**). One is entitled "Characterization of ADAMTS14, a novel member of the ADAMTS metalloproteinase family" by Bolz *et al.*, 2001 (Biochim Biophys Acta. 1522:221-5, 2001). A second is entitled "Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3" by Colige, *et al.*, 2002 (J Biol Chem. 277:5756-66, 2002, Epub 2001 Dec 07). The third is entitled "Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains" by Cal, *et al.*, 2002 (Gene 283:49-62).

Applicants respectfully submit that these publications constitutes evidence that clearly demonstrates that the proteins of the present invention have function and utility that are both accepted by those skilled in the art. As the legal test for utility simply involves an assessment of whether those skilled in the art would find any of the utilities described for the invention to be credible or believable. Clearly those of skill in the art would recognize that molecules that share such amino acid sequence homology would share protein structure and would thus would also share the same function. This constitutes evidence that clearly supports the specifications assertion that SEQ ID NO:19 and 20 encode a known protein (the metalloprotease ADAMSTS14).

Applicants submit that the presently claimed molecules have been shown to encode, as asserted in the specification as filed, ADAMTS-14 precursor (A disintegrin and metalloproteinase with thrombospondin motifs 14) (ADAM-TS 14) which is known to the art. Thus, the present situation directly tracks Example 10 of the Revised Interim Utility Guidelines Training Materials (pages 53-55), which establishes that a rejection under 35 U.S.C. § 101 as allegedly lacking a patentable utility and

under 35 U.S.C. § 112, first paragraph as allegedly unusable by the skilled artisan due to the alleged lack of patentable utility, is not proper when a full length sequence (such as the presently claimed sequence), and has a similarity score greater than 95% to a protein having a known function (such as the 100% identity between the presently claimed sequences and those of the cited protein (Q8WXS8).

Further evidence of utility of the presently claimed polynucleotide, although only one is needed to meet the requirements of 35 U.S.C. § 101 (*Raytheon v. Roper*, 220 USPQ 592 (Fed. Cir. 1983); *In re Gottlieb*, 140 USPQ 665 (CCPA 1964); *In re Malachowski*, 189 USPQ 432 (CCPA 1976); *Hoffman v. Klaus*, 9 USPQ2d 1657 (Bd. Pat. App. & Inter. 1988)), is the specific utility the present nucleotide sequence has in determining the genomic structure of the corresponding human chromosome, for example mapping the protein encoding regions as described in the specification. As evidence supporting Applicants assertions of the specific utility of the sequences of the present invention in localizing the specific region of the human chromosome and identification of functionally active intron/exon splice junctions is the information provided as **Exhibit E**. This is the result of overlaying the sequence of SEQ ID NO:19 of the present invention and the identified human genomic sequence. By doing this, one is able to identify the portions of the genome that encode the present invention. If these regions of the genome are non-contiguous, this is indicative of individual exons. The results of such an analysis indicates that the sequence of the present invention is encoded by at least 24 exons spread non-contiguously along a region of human chromosome 10, which are contained within four BAC clones AL335344.20, AC007484.2, AC069538.10 and AC007484.2. Thus clearly one would not simply be able to identify the 24 or more protein encoding exons that make up the sequence of the present invention from within the large genomic sequence. Nor, would one be able to map the protein encoding regions identified specifically by the sequences of the present invention without knowing exactly what those specific sequences were. Additionally, it should be noted that the human ADAMSTS14 gene also maps to the same region of human chromosome 10 (at approximately 10q2). This further supports Applicant's position that the sequences of the present invention encodes a variant of the human ADAMSTS14.

Therefore, clearly, the present polynucleotide provides exquisite specificity in localizing the specific region of the human chromosome containing the gene encoding the given polynucleotide, a utility not shared by virtually any other nucleic acid sequence. In fact, it is this specificity that makes this

particular sequence so useful. Early gene mapping techniques relied on methods such as Giemsa staining to identify regions of chromosomes. However, such techniques produced genetic maps with a resolution of only 5 to 10 megabases, far too low to be of much help in identifying specific genes involved in disease. The skilled artisan readily appreciates the significant benefit afforded by markers that map a specific locus of the human genome, such as the present nucleic acid sequence.

Only a minor percentage of the genome actually encodes exons, which in turn encode amino acid sequences. The presently claimed polynucleotide sequence provides biologically validated empirical data (*e.g.*, showing which sequences are transcribed, spliced, and polyadenylated) that *specifically* defines that portion of the corresponding genomic locus that actually encodes exon sequence. Equally significant is that the claimed polynucleotide sequence defines how the encoded exons are actually spliced together to produce an active transcript (*i.e.*, the described sequences are useful for functionally defining exon splice-junctions). The Applicants respectfully submit that the practical scientific value of expressed, spliced, and polyadenylated mRNA sequences is readily apparent to those skilled in the relevant biological and biochemical arts. The presently claimed polynucleotide sequence defines a biologically validated sequence that provides a unique and specific resource for mapping the genome.

An additional utility includes the use of the presently claimed polynucleotides on DNA chips. Further, the Action seems to be requiring Applicants to identify the biological role of the nucleic acid or function of the protein encoded by the presently claimed polynucleotides before the present sequences can be used in gene chip applications that meet the requirements of § 101. Applicants respectfully point out that knowledge of the exact function or role of the presently claimed sequence is not required to track expression patterns using a DNA chip. Given the widespread utility of such "gene chip" methods using *public domain* gene sequence information, there can be little doubt that the use of the presently described *novel* sequences would have great utility in such DNA chip applications. The claimed sequence provides a specific marker of the human genome (see evidence below), and that such specific markers are targets for discovering drugs that are associated with human disease. Thus, those skilled in the art would instantly recognize that the present nucleotide sequence would be an ideal, novel candidate for assessing gene expression using, for example, DNA chips, as the specification details. Such "DNA chips" clearly have utility, as evidenced by hundreds of issued U.S. Patents, as

exemplified by U.S. Patent Nos. 5,445,934, 5,556,752, 5,744,305, as well as more recently issued U.S. Patent Nos. 5,837,832, 6,156,501 and 6,261,776. Accordingly, the present sequence has a specific utility in such DNA chip applications. Clearly, compositions that enhance the utility of such DNA chips, such as the presently claimed nucleotide sequence, must also be useful.

Additionally, since only a small percentage of the genome (2-4%) actually encodes exons, which in-turn encode amino acid sequences. Thus, not all human genomic DNA sequences are useful in such gene chip applications. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101. It has been clearly established that a statement of utility in a specification must be accepted absent reasons why one skilled in the art would have reason to doubt the objective truth of such statement. *In re Langer*, 503 F.2d 1380, 1391, 183 USPQ 288, 297 (CCPA, 1974); *In re Marzocchi*, 439 F.2d 220, 224, 169 USPQ 367, 370 (CCPA, 1971).

Evidence of the "real world" substantial utility of the present invention is further provided by the fact that there is an entire industry established based on the use of gene sequences or fragments thereof in a gene chip format. Perhaps the most notable gene chip company is Affymetrix. However, there are many companies which have, at one time or another, concentrated on the use of gene sequences or fragments, in gene chip and non-gene chip formats, for example: Gene Logic, ABI-Perkin-Elmer, HySeq and Incyte. In addition, one such company, Rosetta Inpharmatics, was viewed to have such "real world" value that it was acquired by large pharmaceutical company, Merck & Co., for substantial sums of money (net equity value of the transaction was \$620 million). The "real world" substantial industrial utility of gene sequences or fragments would, therefore, appear to be widespread and well established. Clearly, persons of skill in the art, as well as venture capitalists and investors, readily recognize the utility, both scientific and commercial, of genomic data in general, and specifically human genomic data. Billions of dollars have been invested in the human genome project, resulting in useful genomic data (see, *e.g.*, Venter *et al.*, 2001, *Science* 291:1304). The results have been a stunning success as the utility of human genomic data has been widely recognized as a great gift to humanity (see, *e.g.*, Jasny and Kennedy, 2001, *Science* 291:1153). Clearly, the usefulness of human genomic data, such as the presently claimed nucleic acid molecules, is substantial and credible (worthy of billions of dollars and the creation of numerous companies focused on such information) and well-established (the utility of human genomic information has been clearly understood for many years). The sequences of

the present invention have particularly specific utility in DNA gene chip based analysis as they have been identified to contain several coding region nucleotide polymorphisms (see above), thus increasing their utility in DNA gene chip based analysis.

Finally, the Examiner is requested to consider the issue of due process. Applicants understanding is that issued United States patents retain a legal presumption of validity which in this case indicates that the inventions claimed in the cited patents are *legally presumed* to be in full compliance with the provisions of 35 U.S.C. sections 101, 102, 103, and 112. Applicants respectfully submit that, absent a change in the law as enacted by Congress and signed by the President, it is improper for the Examiner to hold Applicants' invention to a different legal standard of patentability. Given the rapid pace of development in the biotechnology arts, it is difficult for the Applicants to understand how an invention fully disclosed and free of prior art at the time the present application was filed, could somehow retain *less* utility and be *less* enabled than inventions in the cited issued U.S. patents (which were filed during a time when the level of skill in the art was clearly lower). Simply put, Applicants invention is *more* enabled and retains *at least as much* utility as the inventions described in the claims of the U.S. patents of record. Any argument to the contrary is at best arbitrary and at worst capricious. Absent authority provided by an act of Congress or Executive order, arbitrary or capricious conduct by an administrative office the U.S. government has historically proven to conflict with the provisions of the U.S. Constitution. The Patent Office does not have the authority to rewrite U.S. law. However, the Patent Office does have a Constitutional obligation to administer U.S. law in an unbiased and procedurally consistent manner. That is what the Applicants are respectfully requesting the Examiner to consider in the present matter. As the issued U.S. Patents cited above are presumed to meet all of the requirements for patentability, including 35 U.S.C. §§ 101 and 112, first paragraph, Applicants respectfully submit that the presently claimed polynucleotide must also meet the requirements of 35 U.S.C. § 101.

Thus in summary, Applicants submit that the presently claimed molecules have been shown to encode, as asserted in the specification as filed, ADAMSTS14 isoforms, whose biological function is known to the art. Thus, the present situation directly tracks Example 10 of the Revised Interim Utility Guidelines Training Materials (pages 53-55), which establishes that a rejection under 35 U.S.C. § 101 as allegedly lacking a patentable utility and under 35 U.S.C. § 112, first paragraph as allegedly unusable

by the skilled artisan due to the alleged lack of patentable utility, is not proper when a full length sequence (such as the presently claimed sequence), and has a similarity score greater than 95% to a protein having a known function. Furthermore this response has described a series of additional substantial, specific, credible and well-established utilities for the present invention. Therefore, Applicants submit that as the presently claimed sequence molecules have been shown to have a substantial, specific, credible and well-established utility, the rejection of the claims under 35 U.S.C. § 101 has been overcome. Thus, Applicants respectfully request that the rejection be withdrawn.

IV. Rejection of Claims 2-5 and 7-11 Under 35 U.S.C. § 112, First Paragraph

The Action next rejects claims 2-5 and 7-11 under 35 U.S.C. § 112, first paragraph, as allegedly the claimed invention is not supported by either a specific asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Applicants respectfully submit that claims 2-5 and 7-11 have been shown to have “a specific, substantial, and credible utility”, as detailed in the section above. Therefore, one skilled in the art would clearly know how to use the claimed invention and Applicants therefore request that the rejection of claims. Therefore, Applicants submit that as the presently claimed sequence molecules have been shown to have a substantial, specific, credible and well-established utility, and thus the rejection of the claims under 35 U.S.C. § 112, first paragraph has been avoided. Thus, Applicants respectfully request that the rejection be withdrawn.

V. Rejection of Claim 7 Under 35 U.S.C. § 112, Second Paragraph

The Action next rejects claim 7 under 35 U.S.C. § 112, second paragraph, as being allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. While Applicants in no way agree, Claim 7 has been amended to replace the term “drawn” with the term ‘selected’.

Therefore, Applicants submit that amended Claim 7 is clearly definite and particularly points out and distinctly claims the subject matter which applicant regards as the invention and thus the rejection of the claim under 35 U.S.C. § 112, first paragraph has been avoided. Applicants, therefore,

respectfully request that the rejection be withdrawn.


VI. Conclusion

The present document is a full and complete response to the Action. In conclusion, Applicants submit that, in light of the foregoing remarks, the present case is in condition for allowance, and such favorable action is respectfully requested. Should Examiner Moore have any questions or comments, or believe that certain amendments of the claims might serve to improve their clarity, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,

August 1, 2003

Date

 Lance K. Ishimoto

Agent for Applicants

Reg. No. No. 41,866

LEXICON GENETICS INCORPORATED
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

Exhibit A
Status of Claims in
U.S. Patent Application Ser. No. 09/938,330

1.(cancelled)

2.(original) An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO: 20; and
- (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 19 or the complement thereof.

3.(original) An isolated nucleic acid molecule according to Claim 2 wherein said nucleotide sequence is present in cDNA.

4.(original) An isolated nucleic acid molecule encoding the amino acid sequence presented in SEQ ID NO:20.

5.(original) An isolated nucleic acid molecule encoding the amino acid sequence presented in SEQ ID NO:22.

6.(cancelled)


7.(currently amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence ~~drawn~~ selected from the group consisting of SEQ ID NOS: 20 and 22.

8.(previously presented) An expression vector comprising a nucleic acid sequence of Claim 4.

9.(previously presented) A cell comprising the expression vector of Claim 8.

10.(previously presented) An expression vector comprising a nucleic acid sequence of Claim 5.

11.(previously presented) A cell comprising the expression vector of Claim 10.



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bio

Search for

Limits

Preview/Index

History

Clipboard

Details

Show: ☐ 1: Q8WXS8. ADAMTS-14 precurs...[gi:29337086]

BLink, Domains, Links

LOCUS Q8WXS8 1223 aa linear PRI 15-SEP-2003
DEFINITION ADAMTS-14 precursor (A disintegrin and metalloproteinase with thrombospondin motifs 14) (ADAM-TS 14) (ADAM-TS14).
ACCESSION Q8WXS8
VERSION Q8WXS8 GI:29337086
DBSOURCE swissprot: locus AT14_HUMAN, accession Q8WXS8;
class: standard.
extra accessions: Q8TE55, Q8TEY8, created: Feb 28, 2003.
sequence updated: Feb 28, 2003.
annotation updated: Sep 15, 2003.
xrefs: gi: 17483853, gi: 17483854, gi: 19171187, gi: 19171188, gi: 18874445, gi: 18874446
xrefs (non-sequence databases): MEROPSM12.024, GenewHGNC:14899, MIM 607506, InterProIPR001762, InterProIPR001818, InterProIPR002870, InterProIPR001590, InterProIPR000884, InterProIPR008085, InterProIPR006025, PfamPF01562, PfamPF01421, PfamPF00090, PRINTSPR01705, SMARTSM00209, PROSITEPS50215, PROSITEPS00546, PROSITEPS00427, PROSITEPS50214, PROSITEPS50092, PROSITEPS00142
KEYWORDS Hydrolase; Metalloprotease; Zinc; Signal; Glycoprotein; Zymogen; Collagen degradation; Repeat; Extracellular matrix; Alternative splicing; Alternative promoter usage.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (residues 1 to 1223)
AUTHORS Bolz, H., Ramirez, A., von Brederlow, B. and Kubisch, C.
TITLE Characterization of ADAMTS14, a novel member of the ADAMTS metalloproteinase family
JOURNAL Biochim. Biophys. Acta 1522 (3), 221-225 (2001)
MEDLINE 21638061
REMARK SEQUENCE FROM N.A. (ISOFORM A).
REFERENCE 2 (residues 1 to 1223)
AUTHORS Cal, S., Obaya, A.J., Llamazares, M., Garabaya, C., Quesada, V. and Lopez-Otin, C.
TITLE Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains
JOURNAL Gene 283 (1-2), 49-62 (2002)
MEDLINE 21856482
REMARK SEQUENCE FROM N.A. (ISOFORM A).
TISSUE=Fetal lung
REFERENCE 3 (residues 1 to 1223)
AUTHORS Colige, A., Vandenberghe, I., Thiry, M., Lambert, C.A., Van Beeumen, J., Li, S.W., Prockop, D.J., Lapiere, C.M. and Nusgens, B.V.
TITLE Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3

JOURNAL J. Biol. Chem. 277 (8), 5756-5766 (2002)
MEDLINE 21839041
REMARK SEQUENCE OF 29-1223 FROM N.A. (ISOFORMS B; C AND D), AND
ALTERNATIVE PROMOTER USAGE.

COMMENT

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. The original entry is available from <http://www.expasy.ch/sprot> and <http://www.ebi.ac.uk/sprot>

[FUNCTION] Has a aminoprocollagen type I activity processing activity in the absence of ADAMTS2. Seems to be synthesized as a latent enzyme that requires activation to display aminoprocollagen peptidase activity.
[SUBCELLULAR LOCATION] Secreted. Associated with the extracellular matrix (By similarity).
[ALTERNATIVE PRODUCTS] Event=Alternative promoter; Comment=2 isoforms, A (shown here) and B, are produced by use of alternative promoters; Event=Alternative splicing; Named isoforms=4; Name=A; IsoId=Q8WXS8-1; Sequence=Displayed; Name=B; IsoId=Q8WXS8-2; Sequence=VSP_006958; Name=C; IsoId=Q8WXS8-3; Sequence=VSP_006958, VSP_005501; Note=Produced by alternative splicing of isoform B; Name=D; IsoId=Q8WXS8-4; Sequence=VSP_005501; Note=Produced by alternative splicing of isoform A.
[TISSUE SPECIFICITY] Expressed in retina and at low levels in brain, lung and placenta. High expression in fetal tissues.
[DOMAIN] The spacer domain and the TSP type-1 domains are important for a tight interaction with the extracellular matrix (By similarity).
[PTM] The precursor is cleaved by a furin endopeptidase (By similarity).
[SIMILARITY] Belongs to peptidase family M12B.
[SIMILARITY] Contains 1 disintegrin-like domain.
[SIMILARITY] Contains 1 PLAC domain.
[SIMILARITY] Contains 4 TSP type-1 domains.

FEATURES

	Location/Qualifiers
source	1..1223 /organism="Homo sapiens" /db_xref="taxon:9606"
gene	1..1223 /gene="ADAMTS14"
Protein	1..1223 /gene="ADAMTS14" /product="ADAMTS-14 precursor" /EC_number="3.4.24.-"
Region	1..68 /gene="ADAMTS14" /region_name="Splicing variant" /note="Missing (in isoform B and isoform C)." /FTId=VSP_006958."
Region	1..22 /gene="ADAMTS14" /region_name="Signal" /note="POTENTIAL."
Region	23..252 /gene="ADAMTS14" /region_name="Propeptide" /note="BY SIMILARITY."
Site	109

Region /gene="ADAMTS14"
/site_type="glycosylation"
/note="N-LINKED (GLCNAC...) (POTENTIAL)."
253..1223

Region /gene="ADAMTS14"
/region_name="Mature chain"
/note="ADAMTS-14."
253..460

Region /gene="ADAMTS14"
/region_name="Domain"
/note="METALLOPROTEASE."
368

Site /gene="ADAMTS14"
/region_name="Splicing variant"
/note="G -> GMQG (in isoform C and isoform D).
/FTId=VSP_005501."
398

Site /gene="ADAMTS14"
/site_type="metal-binding"
/note="ZINC (CATALYTIC) (BY SIMILARITY)."
399

Site /gene="ADAMTS14"
/site_type="active"
/note="BY SIMILARITY."
402

Site /gene="ADAMTS14"
/site_type="metal-binding"
/note="ZINC (CATALYTIC) (BY SIMILARITY)."
408

Region /gene="ADAMTS14"
/site_type="metal-binding"
/note="ZINC (CATALYTIC) (BY SIMILARITY)."
461..551

Site /gene="ADAMTS14"
/region_name="Domain"
/note="DISINTEGRIN-LIKE."
475

Region /gene="ADAMTS14"
/site_type="glycosylation"
/note="N-LINKED (GLCNAC...) (POTENTIAL)."
552..607

Region /gene="ADAMTS14"
/region_name="Domain"
/note="TSP TYPE-1 1."
608..729

Region /gene="ADAMTS14"
/region_name="Domain"
/note="CYS-RICH."
730..846

Region /gene="ADAMTS14"
/region_name="Domain"
/note="SPACER."
847..907

Region /gene="ADAMTS14"
/region_name="Domain"
/note="TSP TYPE-1 2."
868

Region /gene="ADAMTS14"
/region_name="Conflict"
/note="Q -> R (IN REF. 2)."

Region 875..878
/gene="ADAMTS14"
/region_name="Domain"
/note="POLY-ARG."

Region 884
/gene="ADAMTS14"
/region_name="Conflict"
/note="Q -> H (IN REF. 2)."

Region 901
/gene="ADAMTS14"
/region_name="Conflict"
/note="C -> S (IN REF. 2)."

Region 908..967
/gene="ADAMTS14"
/region_name="Domain"
/note="TSP TYPE-1 3."

Region 923
/gene="ADAMTS14"
/region_name="Conflict"
/note="C -> Y (IN REF. 2)."

Site 941
/gene="ADAMTS14"
/site_type="glycosylation"
/note="N-LINKED (GLCNAC...) (POTENTIAL)."

Region 968..1022
/gene="ADAMTS14"
/region_name="Domain"
/note="TSP TYPE-1 4."

Region 1024
/gene="ADAMTS14"
/region_name="Conflict"
/note="N -> S (IN REF. 2)."

Site 1027
/gene="ADAMTS14"
/site_type="glycosylation"
/note="N-LINKED (GLCNAC...) (POTENTIAL)."

Region 1063..1093
/gene="ADAMTS14"
/region_name="Domain"
/note="PLAC."

Region 1100..1221
/gene="ADAMTS14"
/region_name="Domain"
/note="PRO-RICH."

ORIGIN

```
1 maplrallsy llplhcalca aagsrtpelh lsgklstdygv tvpcstdfrg rflshvvsqp
61 aaasagsmvv dtpptlprhs shlrvarspl hpggtlwpgr vgrhslyfnv tvfgkelhlr
121 lrpnrrlvvp gssvewqedf relfrqplrq ecvytggvtg mpgaavaish cdglaglirt
181 dstdffiepl ergqqeikas grthvvyrrr avqgewaepd gdlhneafgl gdlpnllglv
241 gdqlgdterk rrrhakpgsys ievlllvdds vvrhfgkehv qnyvltlmi vdeiyhdesl
301 gvhinialvr limvgyrqsl sliernpsr sleqvrwah sqqrqdpsha ehhdhvflt
361 rqdfgpgsya pvtgmchplr scalnhedgf ssafviahet ghvlgmehdg qngcadets
421 lgsvmaplva aafhrfhwsr csklelsryl psydcclldp fdpawpqppe lpginysmde
481 qcrfdfgsgy qtclaftrfe pckqlwcshp dnpyfcktkk gppldgteca pgkwcfkghc
541 iwkspqetyg qdggwsswtk fgscsrscgg gvrssrsrscn npspayggrp clgpmfeyqv
601 cnseecpgty edfraqqcak rnsyyvhqna khswvpyped ddaqkcelic qsadtgdvvf
661 mnqvvhdgtr csyrdpysvc argecvpvcg dkevgsmkad dkcgvcggdn shcrtvkgtl
721 gkaskqagal klvqipagar hiqiealeks phrivvknqv tgsfilnpgk keatsrtfta
781 mglewedave dakeslktsg plpeaiaila lppteggprs slaykyvihe dllpligsnn
841 vlleemdtie walkswapcs kacgggiqft kygcrrrrdh hmvqrhlcdh kkrpkpirrr
```

901 cnqhpcsqpv wvteewgacs rscgklgvqt rgiqcclpls ngthkvpak acagdrpear
961 rpclrvpcpa qwrlgawsqc satcgegiqq rqvvcrtan slghcegdrp dtvqvcsipa
1021 cggnhqnstv radvwelgtp egqwvpqsep lhpinkisst epctgdrsvf cqmevldryc
1081 sipgyhrlec vscikkasgp npgpdpgpts lppfstpgsp lpgpqdpada aeppgkptgs
1141 edhqhgratq lpgaldtssp gtqhpafapet pipgaswsis pttpggplpwg wtqtptpvpe
1201 dkgqpgedlr hpgtsipaas pvt

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jul 17 2003 11:56:53



FASTA searches a protein or DNA sequence data bank
version 3.3t05 March 30, 2000

Please cite:

W.R. Pearson & D.J. Lipman PNAS (1988) 85:2444-2448

/tmp/fastaCAARWaOhY: 1252 aa
>Lex 221 SEQ ID NO:20
vs /tmp/fastaDAASWaOhY library
searching /tmp/fastaDAASWaOhY library

1223 residues in 1 sequences

FASTA (3.34 January 2000) function [optimized, BL50 matrix (15:-5)] ktup: 2
join: 40, opt: 28, gap-pen: -12/ -2, width: 16
Scan time: 0.067

The best scores are: opt
gi|29337086|sp|Q8WXS8|AT14_HUMAN ADAMTS-14 precur (1223) 8686

>>gi|29337086|sp|Q8WXS8|AT14_HUMAN ADAMTS-14 precursor ((1223 aa)
initn: 8683 init1: 7506 opt: 8686
Smith-Waterman score: 8686; 98.611% identity in 1224 aa overlap (1-1224:1-1221)

	10	20	30	40	50	60
Lex	MAPLRALLSYLLPLHCAALCXAAAGSRTPELHLSGKLSDYGVTVPCSTDFRGRFLSHVVS					
					
gi 293	MAPLRALLSYLLPLHCAALCAAAGSRTPELHLSGKLSDYGVTVPCSTDFRGRFLSHVVS					
	10	20	30	40	50	60
					
Lex	70	80	90	100	110	120
	AAASAGSMVVDTPPTLPRHSSHLRVARSPHPGGTLWPGRVGRHSLYFNVTVFGKELHLR					
					
gi 293	AAASAGSMVVDTPPTLPRHSSHLRVARSPHPGGTLWPGRVGRHSLYFNVTVFGKELHLR					
	70	80	90	100	110	120
					
Lex	130	140	150	160	170	180
	LRPNRRLVVPGSSVEWQEDFRELFRQPLRQECVYTGCVTGMPGA AVAISNCDGLAGLIRT					
					
gi 293	LRPNRRLVVPGSSVEWQEDFRELFRQPLRQECVYTGCVTGMPGA AVAISNCDGLAGLIRT					
	130	140	150	160	170	180
					
Lex	190	200	210	220	230	240
	DSTDFFIEPLERGQKEASGRTHVVYRREAVQQEWAEPDGLHNEAFGLGDLPNLLGLV					
					
gi 293	DSTDFFIEPLERGQKEASGRTHVVYRREAVQQEWAEPDGLHNEAFGLGDLPNLLGLV					
	190	200	210	220	230	240
					
Lex	250	260	270	280	290	300
	GDQLGDTERKRRHAKPGSYSIEVLLVVDDSVVRFHGKEHVQNYVLTLMNIVDEIYHDESL					
					
gi 293	GDQLGDTERKRRHAKPGSYSIEVLLVVDDSVVRFHGKEHVQNYVLTLMNIVDEIYHDESL					
	250	260	270	280	290	300
					
Lex	310	320	330	340	350	360
	GVHINIALVRLIMVGYRQSLIERGNPSRSLEQVCRWAHSQQRQDP SHAEHHDHVVF					
					
gi 293	GVHINIALVRLIMVGYRQSLIERGNPSRSLEQVCRWAHSQQRQDP SHAEHHDHVVF					
	310	320	330	340	350	360
					
Lex	370	380	390	400	410	420
	RQDFGPSGYAPVTGMCHPLRSCALNHEDGFSSAFVIAHETGHVLMGMEHDGQNGCADETS					


```

gi|293  RQDFGPSGYAPVTGMCHPLRSCALNHEDGFSSAFVIAHETGHVLMGMEHDGQNGCADETS
          370          380          390          400          410          420
          430          440          450          460          470          480
Lex     LGSVMAPLVQAAFHRFHWSRCSKLELSRYLPSYDCLDDPFDPAWPQPPELPGINYSMDE
          .....
gi|293  LGSVMAPLVQAAFHRFHWSRCSKLELSRYLPSYDCLDDPFDPAWPQPPELPGINYSMDE
          430          440          450          460          470          480
          490          500          510          520          530          540
Lex     QCRFDGSGYQTCLAFRTFEPCKQLWCSPDNXXFCKTKKGPPLDGTECAPGKWCFKGHC
          .....
gi|293  QCRFDGSGYQTCLAFRTFEPCKQLWCSPDNPFCKTKKGPPLDGTECAPGKWCFKGHC
          490          500          510          520          530          540
          550          560          570          580          590          600
Lex     IWKSPEQTYGQDGGWSSWTKFGSCSRSCGGGVRSRSCNNPSPAYGGRXCLGPMFEYQV
          .....
gi|293  IWKSPEQTYGQDGGWSSWTKFGSCSRSCGGGVRSRSCNNPSPAYGGRPCLGPMFEYQV
          550          560          570          580          590          600
          610          620          630          640          650          660
Lex     CNSEECPGTYEDFRAQQCAKRNSYYVHQNAKHSWVPYEPDDDAQKCELICQSADTGDVVF
          .....
gi|293  CNSEECPGTYEDFRAQQCAKRNSYYVHQNAKHSWVPYEPDDDAQKCELICQSADTGDVVF
          610          620          630          640          650          660
          670          680          690          700          710          720
Lex     MNQVVHDGTRCSYRDPYSVCARGECVPVGCDEKVGSMKADDKCGVCGGDNSHCRTVKGTL
          .....
gi|293  MNQVVHDGTRCSYRDPYSVCARGECVPVGCDEKVGSMKADDKCGVCGGDNSHCRTVKGTL
          670          680          690          700          710          720
          730          740          750          760          770          780
Lex     GKASKQAGALKLVQIPAGARHIQIEALEKSPHXXVVKNQVTGSFILNPKGKEATSRTFTA
          .....
gi|293  GKASKQAGALKLVQIPAGARHIQIEALEKSPHRIVVKNQVTGSFILNPKGKEATSRTFTA
          730          740          750          760          770          780
          790          800          810          820          830          840
Lex     MGLEWEDAVIDAKESLKTSGPLPEAIAIALPPTEGGPRSSLAYKYVIHEDLLPLIGSNN
          .....
gi|293  MGLEWEDAVIDAKESLKTSGPLPEAIAIALPPTEGGPRSSLAYKYVIHEDLLPLIGSNN
          790          800          810          820          830          840
          850          860          870          880          890          900
Lex     VLLEEMDTYEWALKSWAPCSKACGGGIQFTKYGCRRRRDHMVQRHLCDHKKRPKPIRRR
          .....
gi|293  VLLEEMDTYEWALKSWAPCSKACGGGIQFTKYGCRRRRDHMVQRHLCDHKKRPKPIRRR
          850          860          870          880          890          900
          910          920          930          940          950          960
Lex     CNQHPCSQPVVWTEEWGACSRSCGKLGVTGRIQCLLPLSNGTHKVMPPAKACAGDRPEAR
          .....
gi|293  CNQHPCSQPVVWTEEWGACSRSCGKLGVTGRIQCLLPLSNGTHKVMPPAKACAGDRPEAR
          910          920          930          940          950          960
          970          980          990          1000         1010         1020
Lex     RPCLRVPCPAQWRLGAWSQCSATCGEGIQQRQVVCRTNANSLGHCEGDRPDTVQCXLPA

```

```
gi|293 RPCLRVPCPAQWRLGAWSQCSATCGEGIQQRQVVCRTNANSLGHCEGDRPDTVQVCSLPA
          970          980          990          1000          1010          1020
Lex      CGGNHQNSTVRADVWELGTPEGQWVPQ SXPLHPINKISSMCAAEPCTGDRSVFCQMEVLD
          1030          1040          1050          1060          1070          1080
gi|293 CGGNHQNSTVRADVWELGTPEGQWVPQSEPLHPINKISS---TEPCTGDRSVFCQMEVLD
          1030          1040          1050          1060          1070
Lex      RYCSIPGYHRLCCVSCIKKASGPNPGPDGPTSLPPFSTPGSPLPGPQDPADAAEPPGKP
          1090          1100          1110          1120          1130          1140
gi|293 RYCSIPGYHRLCCVSCIKKASGPNPGPDGPTSLPPFSTPGSPLPGPQDPADAAEPPGKP
          1080          1090          1100          1110          1120          1130
Lex      TGSEDHQHGRATQLPGALDTSSPGTQHHPFAPETPIPGASWSISPTTPGGLPWGWTQTPTP
          1150          1160          1170          1180          1190          1200
gi|293 TGSEDHQHGRATQLPGALDTSSPGTQHHPFAPETPIPGASWSISPTTPGGLPWGWTQTPTP
          1140          1150          1160          1170          1180          1190
Lex      VPEDKGQPGEDLRHPGTSLPADLPGRPPEPCHPTGTFTLCVLPRDSQLRGHT
          1210          1220          1230          1240          1250
gi|293 VPEDKGQPGEDLRHPGTSLPAASPVT
          1200          1210          1220
```

1252 residues in 1 query sequences

1223 residues in 1 library sequences

Scomplib [version 3.3t05 March 30, 2000]

start: Tue Jul 29 17:17:39 2003 done: Tue Jul 29 17:17:40 2003

Scan time: 0.067 Display time: 2.117

Function used was FASTA



EXHIBIT "D"

J Biol Chem. 2002 Feb 22;277(8):5756-66. Epub 2001 Dec 07.

[Related Articles, Links](#)

Full text article at
www.jbc.org

Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3.

Colige A, Vandenberghe I, Thiry M, Lambert CA, Van Beeumen J, Li SW, Prockop DJ, Lapiere CM, Nusgens BV.

Laboratory of Connective Tissues Biology, Experimental Cancerology Research Center, Tour de Pathologie (B23/3), University of Liege, B-4000 Liege, Belgium.

The processing of amino- and carboxyl-propeptides of fibrillar collagens is required to generate collagen monomers that correctly assemble into fibrils. Mutations in the ADAMTS2 gene, the aminopropeptidase of procollagen I and II, result in the accumulation of non-fully processed type I procollagen, causing human Ehlers-Danlos syndrome type VIIC and animal dermatosparaxis. In this study, we show that the aminopropeptide of type I procollagen can be cleaved in vivo in absence of ADAMTS-2 activity and that this processing is performed at the cleavage site for ADAMTS-2. In an attempt to identify the enzyme responsible for this alternative aminoprocollagen peptidase activity, we have cloned the cDNA and determined the primary structure of human and mouse ADAMTS-14, a novel ADAMTS displaying striking homologies with ADAMTS-2 and -3. The structure of the human gene, which maps to 10q21.3, and the mechanisms of generation of the various transcripts are described. The existence of two sites of initiation of transcription, in two different promoter contexts, suggests that transcripts resulting from these two sites can be differently regulated. The tissue distribution of ADAMTS-14, the regulation of the gene expression by various cytokines and the activity of the recombinant enzyme are evaluated. The potential function of ADAMTS-14 as a physiological aminoprocollagen peptidase in vivo is discussed.

PMID: 11741898 [PubMed - indexed for MEDLINE]




Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.

Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C.

Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006, Oviedo, Spain.

ADAMTS (A Disintegrin And Metalloproteinase domain, with ThromboSpondin type-1 modules) is a recently described family of zinc-dependent proteases which play important roles in a variety of normal and pathological conditions, including arthritis and cancer. In this work, we report the identification and cloning of cDNAs encoding seven new human ADAMTSs. These novel enzymes have been called ADAMTS-13, -14, -15, -16, -17, -18, and -19. All of them show a domain organization similar to that of previously characterized family members, consisting of a signal sequence, a propeptide, a metalloproteinase domain, a disintegrin-like domain, a cysteine-rich region, and a variable number of TS-1 repeats. Expression analysis revealed that these ADAMTS genes are mainly expressed in fetal tissues, especially in lung (ADAMTS14, ADAMTS16, ADAMTS17, ADAMTS18, and ADAMTS19), kidney (ADAMTS14, ADAMTS15, and ADAMTS16), and liver (ADAMTS13, ADAMTS15 and ADAMTS18). Reverse transcriptase--polymerase chain reaction analysis also revealed the expression of some of these new ADAMTSs in different human adult tissues, such as prostate (ADAMTS13, ADAMTS17, and ADAMTS18), and brain (ADAMTS13, ADAMTS16, ADAMTS17, and ADAMTS18). High levels of ADAMTSs transcripts were also observed in some tumor biopsies and cells lines, including osteosarcomas (ADAMTS19), melanoma and colon carcinoma cells (ADAMTS13). Chromosomal location analysis indicated that the seven identified ADAMTS genes are dispersed in the human genome mapping to 9q34, 10q21, 11q25, 5p15, 15q24, 16q23, and 5q31, respectively. According to these results, together with a comparative analysis of ADAMTSs in other eukaryotic organisms, we conclude that these enzymes, with at least 18 distinct members encoded within the human genome, represent an example of a widely expanded protease family during metazoan evolution.

PMID: 11867212 [PubMed - indexed for MEDLINE]



Characterization of ADAMTS14, a novel member of the ADAMTS metalloproteinase family.

Bolz H, Ramirez A, von Brederlow B, Kubisch C.

Institut für Hämangioendotheliale Angiogenese, Universitäts-Klinikum Eppendorf, Hamburg, Germany.
bolz@uke.uni-hamburg.de

ADAMTS (a disintegrin-like and metalloproteinase domain with thrombospondin type 1 modules) proteins constitute a family of zinc metalloproteinases which target and process extracellular matrix proteins. We cloned and characterized a novel human ADAMTS gene, ADAMTS14, which is located on human chromosome 10q2. ADAMTS14 exhibits the characteristic multidomain structure of ADAMTS proteins including four thrombospondin modules and shows highest similarity to ADAMTS3 and ADAMTS2. By RT-PCR analysis we demonstrated that ADAMTS14 is expressed in human retina and also at low levels in adult brain, lung and placenta.

PMID: 11779638 [PubMed - indexed for MEDLINE]



EXHIBIT "E"

MegaBlast

MEGABLAST 1.2.3-Paracel [2001-11-20]

Reference:

Zheng Zhang, Scott Schwartz, Lukas Wagner, and Webb Miller (2000),

"A greedy algorithm for aligning DNA sequences",

J Comput Biol 2000; 7(1-2):203-14.

Database: Homo_sapiens.latestgp.masked.fa

33,840 sequences; 200,810,911,373 total letters

Query= LEX221seqid19
(3759 letters)

Sequences producing significant alignments:

Score (bits)	E Value
-----------------	------------

AL355344.20.1.149490	882	0.0
AC007484.2.50228.57677	854	0.0
AC069538.10.1.169772	654	0.0
AC007484.2.23991.29266	654	0.0
AC007484.2.57778.65289	387	e-104
AC007484.2.112555.124636	314	3e-82
AC010216.8.1.110753	139	1e-29

>AL355344.20.1.149490
Length = 149490

Score = 882 bits (444), Expect = 0.0
Identities = 444/444 (100%)
Strand = Plus / Plus

Query: 80 cagagctgcacctctctggaaagctcagtgactatggtgtgacagtgccctgcagcacag 139
|||||
Sbjct: 147159 cagagctgcacctctctggaaagctcagtgactatggtgtgacagtgccctgcagcacag 147218

Query: 140 actttcggggacgcttctctccacgtggtgtctggcccagcagcagcctctgcagggg 199
|||||
Sbjct: 147219 actttcggggacgcttctctccacgtggtgtctggcccagcagcagcctctgcagggg 147278

Query: 200 gcatggtagtggacacgccacccacactaccacgacactccagtcacctccgggtggctc 259
|||||
Sbjct: 147279 gcatggtagtggacacgccacccacactaccacgacactccagtcacctccgggtggctc 147338

Query: 260 gcagccctctgcacccaggagggaccctgtggcctggcaggggtggggcgccactccctct 319
|||||
Sbjct: 147339 gcagccctctgcacccaggagggaccctgtggcctggcaggggtggggcgccactccctct 147398

Query: 320 acttcaatgtcactgttttcgggaaggaactgcacttgccgctgcccgaatcgagggt 379
|||||
Sbjct: 147399 acttcaatgtcactgttttcgggaaggaactgcacttgccgctgcccgaatcgagggt 147458

Query: 380 tggtagtgccaggatcctcagtggagtggcaggaggattttcgggagctgttccggcagc 439

Sbjct: 147459 |tggtagtgcaggatcctcagtggagtggcaggaggattttcgggagctgttccggcagc| 147518

Query: 440 ccttacggcaggagtgtgtgtacactggaggtgtcactggaatgcctggggcagctgttg 499

Sbjct: 147519 |ccttacggcaggagtgtgtgtacactggaggtgtcactggaatgcctggggcagctgttg| 147578

Query: 500 ccatcagcaactgtgacggattgg 523

Sbjct: 147579 |ccatcagcaactgtgacggattgg| 147602

Score = 159 bits (80), Expect = 1e-35

Identities = 81/82 (98%)

Strand = Plus / Plus

Query: 1 atggctccactccgcgcgtgctgtcctacctgctgcctttgactgtgcgctctgcrc 60

Sbjct: 145409 |atggctccactccgcgcgtgctgtcctacctgctgcctttgactgtgcgctctgcgc| 145468

Query: 61 gccgcgggcagccggaccccag 82

Sbjct: 145469 |gccgcgggcagccggaccccag| 145490

>AC007484.2.50228.57677

Length = 7450

Score = 854 bits (430), Expect = 0.0

Identities = 441/444 (99%), Gaps = 3/444 (0%)

Strand = Plus / Minus

Query: 80 cagagctgcacctctctggaaagctcagtgactatggtgtgacagtgccctgcagcacag 139

Sbjct: 5458 |cagagctgcacctctctggaaagctcagtgactatggtgtgacagtgccctgcagcacag| 5399

Query: 140 actttcggggacgcttcctctccacgtggtgtctggcccagcagcagcctctgcaggg 199

Sbjct: 5398 |actttcggggacgcttcctctccacgtggtgtctggcccagcagcagcctctgcaggg| 5339

Query: 200 gcatggtagtggacacgccacccacactaccacgacactccagtcacctccgggtggctc 259

Sbjct: 5338 |gcatggtagtggacacgccacccacactaccacgacactccagtcacctccgggtggctc| 5279

Query: 260 gcagccctctgcacccaggagggaccctgtggcctggcaggggtggggcgccactccctct 319

Sbjct: 5278 |gcagccctctgcacccaggagggaccctgtggcctggcaggggtggggcgccactccctct| 5219

Query: 320 acttcaatgtcactgttttcgggaaggaactgcacttgcgccctgcggcccaatcggaggt 379
|||||
Sbjct: 5218 acttcaatgtcactgttttcgggaaggaactgcacttgcg--tcggcccaatcggaggt 5161

Query: 380 tggtagtgccaggatcctcagtggagtggcaggaggattttcgggagctgttcgggcagc 439
|||||
Sbjct: 5160 tggtagtgccaggatcctcagtggagtggcaggaggattttcgggagctgttcgggcag- 5102

Query: 440 ccttacggcaggagtgtgtgtacactggaggtgtcactggaatgcctggggcagctgttg 499
|||||
Sbjct: 5101 ccttacggcaggagtgtgtgtacactggaggtgtcactggaatgcctggggcagctgttg 5042

Query: 500 ccatcagcaactgtgacggattgg 523
|||||
Sbjct: 5041 ccatcagcaactgtgacggattgg 5018

Score = 133 bits (67), Expect = 7e-28
Identities = 79/83 (95%), Gaps = 3/83 (3%)
Strand = Plus / Minus

Query: 1 atggctccactccgcgcgctgctgtcctacctgctgcctttgc-actgtgcgctctgcrc 59
|||||
Sbjct: 7207 atggctccactccgcgcgctgctgtcctacctgctgcctttgcaactgt-cgctctgcgc 7149

Query: 60 cgccgcgggcagccggacccag 82
|
Sbjct: 7148 c-cgcgggcagccggacccag 7127

>AC069538.10.1.169772
Length = 169772

Score = 654 bits (329), Expect = 0.0
Identities = 336/338 (99%), Gaps = 1/338 (0%)
Strand = Plus / Minus

Query: 3337 tcactgcccccttctccactcctggaagccccttaccaggacccagaccctgcagat 3396
|||||
Sbjct: 132825 tcactgcccccttctccactcctggaagccccttaccaggacccagaccctgcagat 132766

Query: 3397 gctgcagagcctcctggaaagccaacgggatcagaggaccatcagcatggccgagccaca 3456
|||||
Sbjct: 132765 gctgcagagcctcctggaaagccaacgggatcagaggaccatcagcatggccgagccaca 132706

Query: 3457 cagctcccaggagctctggatacaagctccccagggacccagcatccctttgcccctgag 3516
|||||
Sbjct: 132705 cagctcccaggagctctggatacaagctccccagggacccagcatccctttgcccctgag 132646

Query: 3517 acaccaatccctggagcatcctggagcatctcccctaccacccccggggggctgccttgg 3576
|||||
Sbjct: 132645 acaccaatccctggagcatcctggagcatctcccctaccacccccggggggctgccttgg 132586

Query: 3577 ggctggactcagacacctacgccagtcctgaggacaaagggcaacctggagaagacctg 3636
|||||
Sbjct: 132585 ggctggactcagacacctacgccagtcctgaggacaaagggcaacctggagaagacctg 132526

Query: 3637 agacatcccggcaccagcctccctgctgacctgcccgg 3674
|||||
Sbjct: 132525 agacatcccggcaccagcctccctgctg-cctccccg 132489

Score = 405 bits (204), Expect = e-110
Identities = 207/208 (99%)
Strand = Plus / Minus

Query: 2730 gtgggtgacggaggagtgggggtgcctgcagccggagctgtgggaagctgggggtgcagac 2789
|||||
Sbjct: 139531 gtgggtgacggaggagtgggggtgcctgcagccggagctgtgggaagctgggggtgcagac 139472

Query: 2790 acgggggatacagtgcctgctgcccctctccaatggaaccacacaaggatcatgccggccaa 2849
|||||
Sbjct: 139471 acgggggatacagtgcctgctgcccctctccaatggaaccacacaaggatcatgccggccaa 139412

Query: 2850 agcctgcgccggggacgggcctgaggcccgacggccctgtctccgagtgccctgccagc 2909
|||||
Sbjct: 139411 agcctgtgcccggggacgggcctgaggcccgacggccctgtctccgagtgccctgccagc 139352

Query: 2910 ccagtggaggctgggagcctgggtcccag 2937
|||||
Sbjct: 139351 ccagtggaggctgggagcctgggtcccag 139324

Score = 340 bits (171), Expect = 5e-90
Identities = 171/171 (100%)
Strand = Plus / Minus

Query: 2427 ggctctccccccaactgagggtggcccccgacagcctggcctacaagtacgtcatcca 2486
|||||
Sbjct: 141854 ggctctccccccaactgagggtggcccccgacagcctggcctacaagtacgtcatcca 141795

Query: 2487 tgaggacctgctgccccttatcgggagcaacaatgtgctcctggaggagatggacaccta 2546
|||||
Sbjct: 141794 tgaggacctgctgccccttatcgggagcaacaatgtgctcctggaggagatggacaccta 141735

Query: 2547 tgagtggcgctcaagagctgggccccctgcagcaaggcctgtggaggagg 2597
|||||
Sbjct: 141734 tgagtggcgctcaagagctgggccccctgcagcaaggcctgtggaggagg 141684

Score = 338 bits (170), Expect = 2e-89
Identities = 173/176 (98%)
Strand = Plus / Minus

Query: 1749 cccagcctatggaggccgcygtgcttagggcccatgttcgagtaccaggtctgcaacag 1808
|||||
Sbjct: 152344 cccagcctatggaggccgctgtgcttagggcccatgttcgagtaccaggtctgcaacag 152285

Query: 1809 cgaggagtgcctgggacctacgaggacttcggggcccagcagtgtgccaagcgcaactc 1868
|||||
Sbjct: 152284 cgaggagtgcctgggacctacgaggacttcggggcccagcagtgtgccaagcgcaactc 152225

Query: 1869 stactatgtgcaccagaatgccaaagcacagstgggtgccctacgagcctgacgatg 1924
|||||
Sbjct: 152224 ctactatgtgcaccagaatgccaaagcacagctgggtgccctacgagcctgacgatg 152169

Score = 330 bits (166), Expect = 4e-87
Identities = 166/166 (100%)
Strand = Plus / Minus

Query: 2263 gtggtgaagaaccaggtcaccggcagcttcacctcaaccccaagggcaaggaagccaca 2322
|||||
Sbjct: 143510 gtggtgaagaaccaggtcaccggcagcttcacctcaaccccaagggcaaggaagccaca 143451

Query: 2323 agccggaccttcaccgccatgggcctggagtgggaggatgcggtggaggatgccaaaggaa 2382
|||||
Sbjct: 143450 agccggaccttcaccgccatgggcctggagtgggaggatgcggtggaggatgccaaaggaa 143391

Query: 2383 agcctcaagaccagcgggccccctgcctgaagccattgccatcctgg 2428
|||||
Sbjct: 143390 agcctcaagaccagcgggccccctgcctgaagccattgccatcctgg 143345

Score = 306 bits (154), Expect = 7e-80
Identities = 158/159 (99%), Gaps = 1/159 (0%)
Strand = Plus / Minus

Query: 952 cagtcacctgagcctgatcgagcgcgggaacccctcacgcagcctggagcaggtgtgtcgc 1011
|||||
Sbjct: 163232 cagtcacctgagcctgatcgagcgcgggaacccctcacgcagcctggagcaggtgtgtcgc 163173

Query: 1012 tgggcacactcccagcagcgcaggaccccagccacgctgagcaccatgaccacgttgtg 1071
|||||
Sbjct: 163172 tgggcacactcccagcagcgcaggaccccagccacgctgagcaccatgaccacgttgtg 163113

Query: 1072 ttcctcaccgcggcaggactttgggccctcagggatgca 1110
|||||
Sbjct: 163112 ttcctcaccgcggcaggactttgggccctcagg-tatgca 163075

Score = 300 bits (151), Expect = 4e-78
Identities = 151/151 (100%)
Strand = Plus / Minus

Query: 1598 agtgggtgcttcaaaggctactgcatctggaagtcgccggagcagacatatggccaggatg 1657
|||||
Sbjct: 154491 agtgggtgcttcaaaggctactgcatctggaagtcgccggagcagacatatggccaggatg 154432

Query: 1658 gaggctggagctcctggaccaagtttgggtcatgttcgcggtcatgtgggggcgggggtgc 1717
|||||
Sbjct: 154431 gaggctggagctcctggaccaagtttgggtcatgttcgcggtcatgtgggggcgggggtgc 154372

Query: 1718 gatcccgagccggagctgcaacaaccctc 1748
|||||
Sbjct: 154371 gatcccgagccggagctgcaacaaccctc 154341

Score = 286 bits (144), Expect = 6e-74
Identities = 144/144 (100%)
Strand = Plus / Minus

Query: 1209 gctcggcatggagcatgacggtcaggggaatggctgtgcagatgagaccagcctgggcag 1268
|||||
Sbjct: 159446 gctcggcatggagcatgacggtcaggggaatggctgtgcagatgagaccagcctgggcag 159387

Query: 1269 cgtcatggcgcccctgggtgcaggctgccttcaccgcttcattgggtcccgctgcagcaa 1328
|||||
Sbjct: 159386 cgtcatggcgcccctgggtgcaggctgccttcaccgcttcattgggtcccgctgcagcaa 159327

Query: 1329 gctggagctcagccgctacctccc 1352
|||||
Sbjct: 159326 gctggagctcagccgctacctccc 159303

Score = 274 bits (138), Expect = 2e-70
Identities = 138/138 (100%)
Strand = Plus / Minus

Query: 2595 agggatccagttcaccaaatacggctgccggcgagacgagaccaccacatggtgcagcg 2654
|||||
Sbjct: 141238 agggatccagttcaccaaatacggctgccggcgagacgagaccaccacatggtgcagcg 141179

Query: 2655 acacctgtgtgaccacaagaagaggcccaagcccatccgcccggcgctgcaaccagcacc 2714
|||||
Sbjct: 141178 acacctgtgtgaccacaagaagaggcccaagcccatccgcccggcgctgcaaccagcacc 141119

Query: 2715 gtgctctcagcctgtgtg 2732
|||||
Sbjct: 141118 gtgctctcagcctgtgtg 141101

Score = 264 bits (133), Expect = 2e-67
Identities = 134/135 (99%)
Strand = Plus / Minus

Query: 1924 gacgcccagaagtgtgagctgatctgccagtcggcggaacacrggggacgtggtgttcag 1983
|||||
Sbjct: 149784 gacgcccagaagtgtgagctgatctgccagtcggcggaacacrggggacgtggtgttcag 149725

Query: 1984 aaccaggtggttcacgatgggacacgctgcagctaccgggacccatacagcgtctgtgcg 2043
|||||
Sbjct: 149724 aaccaggtggttcacgatgggacacgctgcagctaccgggacccatacagcgtctgtgcg 149665

Query: 2044 cgtggcgagtgtgtg 2058
|||||
Sbjct: 149664 cgtggcgagtgtgtg 149650

Score = 264 bits (133), Expect = 2e-67
Identities = 133/133 (100%)
Strand = Plus / Minus

Query: 1353 ctctacgactgcctcctcgatgacccctttgatcctgcctggccccagccccagagct 1412
|||||
Sbjct: 158162 ctctacgactgcctcctcgatgacccctttgatcctgcctggccccagccccagagct 158103

Query: 1413 gcctgggatcaactactcaatggatgagcagtgccgctttgactttggcagtggtacca 1472
|||||
Sbjct: 158102 gcctgggatcaactactcaatggatgagcagtgccgctttgactttggcagtggtacca 158043

Query: 1473 gacctgcttggca 1485
|||||||
Sbjct: 158042 gacctgcttggca 158030

Score = 262 bits (132), Expect = 1e-66
Identities = 133/134 (99%)
Strand = Plus / Minus

Query: 2935 cagtgtctgtccacctgtggagagggcatccagcagcggcaggtggtgtgcaggaccaac 2994
|||||||
Sbjct: 135372 cagtgtctgtccacctgtggagagggcatccagcagcggcaggtggtgtgcaggaccaac 135313

Query: 2995 gccaacagcctcgggcattgcgagggggataggccagacactgtccaggtctgcarcctg 3054
|||||||
Sbjct: 135312 gccaacagcctcgggcattgcgagggggataggccagacactgtccaggtctgcagcctg 135253

Query: 3055 cccgcctgtggagg 3068
|||||||
Sbjct: 135252 cccgcctgtggagg 135239

Score = 254 bits (128), Expect = 2e-64
Identities = 128/128 (100%)
Strand = Plus / Minus

Query: 3179 tgtgtgcagcggagccctgcacgggagacaggtctgtcttctgccagatggaagtgtctg 3238
|||||||
Sbjct: 132983 tgtgtgcagcggagccctgcacgggagacaggtctgtcttctgccagatggaagtgtctg 132924

Query: 3239 atcgctactgtccattcccggctaccaccggctctgctgtgtgtcctgcatcaagaagg 3298
|||||||
Sbjct: 132923 atcgctactgtccattcccggctaccaccggctctgctgtgtgtcctgcatcaagaagg 132864

Query: 3299 cctcgggc 3306
|||||||
Sbjct: 132863 cctcgggc 132856

Score = 250 bits (126), Expect = 4e-63
Identities = 126/126 (100%)
Strand = Plus / Minus

Query: 2058 gcctgtcggctgtgacaaggaggtgggggtccatgaaggcggatgacaagtgtggagtctg 2117
|||||||

Sbjct: 149266 gcctgtcggctgtgacaaggaggtgggggtccatgaaggcggatgacaagtgtggagtctg 149207

Query: 2118 cggggggtgacaactcccactgcaggactgtgaagggggacgctgggcaaggcctccaagca 2177

Sbjct: 149206 cggggggtgacaactcccactgcaggactgtgaagggggacgctgggcaaggcctccaagca 149147

Query: 2178 ggcagg 2183

Sbjct: 149146 ggcagg 149141

Score = 221 bits (111), Expect = 4e-54
Identities = 112/113 (99%)
Strand = Plus / Minus

Query: 3066 aggaaatcaccagaactccacggtgagggccgatgtctgggaacttgggacgccagaggg 3125

Sbjct: 135158 aggaaatcaccagaactccacggtgagggccgatgtctgggaacttgggacgccagaggg 135099

Query: 3126 gcagtgggtgccacaatctgraccctacatcccattaacaagatatcatcaa 3178

Sbjct: 135098 gcagtgggtgccacaatctgaaccctacatcccattaacaagatatcatcaa 135046

Score = 219 bits (110), Expect = 1e-53
Identities = 112/114 (98%)
Strand = Plus / Minus

Query: 1486 ttcaggacctttgagccctgcaagcagctgtggtgcagccatcctgacaaccmgtayttc 1545

Sbjct: 156651 ttcaggacctttgagccctgcaagcagctgtggtgcagccatcctgacaaccggtacttc 156592

Query: 1546 tgcaagaccaagaaggggccccgcgtggatgggactgagtgtgcacccggcaag 1599

Sbjct: 156591 tgcaagaccaagaaggggccccgcgtggatgggactgagtgtgcacccggcaag 156538

Score = 219 bits (110), Expect = 1e-53
Identities = 110/110 (100%)
Strand = Plus / Minus

Query: 1100 cagggtatgcacccgtcactggcatgtgtcaccccctgaggagctgtgcctcaaccatg 1159

Sbjct: 161080 cagggtatgcacccgtcactggcatgtgtcaccccctgaggagctgtgcctcaaccatg 161021

Query: 1160 aggatggcttctcctcagccttcgtgatagctcatgagaccggccacgtg 1209

|||||
Sbjct: 161020 aggatggcttctcctcagccttcgtgatagctcatgagaccggccacgtg 160971

Score = 167 bits (84), Expect = 5e-38
Identities = 84/84 (100%)
Strand = Plus / Minus

Query: 871 gtagatgagatttaccacgatgagtccttgggggttcatataaatattgccctcgtccgc 930
|||||
Sbjct: 164037 gtagatgagatttaccacgatgagtccttgggggttcatataaatattgccctcgtccgc 163978

Query: 931 ttgatcatggttggctaccgacag 954
|||||
Sbjct: 163977 ttgatcatggttggctaccgacag 163954

Score = 161 bits (81), Expect = 3e-36
Identities = 81/81 (100%)
Strand = Plus / Minus

Query: 2178 ggcaggagctctcaagctggtgcagatcccagcaggtgccaggcacatccagattgaggc 2237
|||||
Sbjct: 148110 ggcaggagctctcaagctggtgcagatcccagcaggtgccaggcacatccagattgaggc 148051

Query: 2238 actggagaagtccccccaccg 2258
|||||
Sbjct: 148050 actggagaagtccccccaccg 148030

Score = 145 bits (73), Expect = 2e-31
Identities = 73/73 (100%)
Strand = Plus / Minus

Query: 3687 gccctgccatcccactggcacgtttacactctgtgtactgccccgtgactcccagctcag 3746
|||||
Sbjct: 132475 gccctgccatcccactggcacgtttacactctgtgtactgccccgtgactcccagctcag 132416

Query: 3747 aggacacacatag 3759
|||||
Sbjct: 132415 aggacacacatag 132403

Score = 89.9 bits (45), Expect = 1e-14
Identities = 66/73 (90%)
Strand = Plus / Minus

Query: 1375 gacccctttgatcctgcctggccccagccccagagctgcctgggatcaactactcaatg 1434
|||||
Sbjct: 158909 gacccctttgagccacctggccccagccccagagctgcccgggatcgacttctcaatg 158850

Query: 1435 gatgagcagtgcc 1447
|||||
Sbjct: 158849 gatgaacagtgcc 158837

>AC007484.2.23991.29266
Length = 5276

Score = 654 bits (329), Expect = 0.0
Identities = 336/338 (99%), Gaps = 1/338 (0%)
Strand = Plus / Minus

Query: 3337 tcaactgcccccttctccactcctggaagccccttaccaggaccccaggaccctgcagat 3396
|||||
Sbjct: 2310 tcaactgcccccttctccactcctggaagccccttaccaggaccccaggaccctgcagat 2251

Query: 3397 gctgcagagcctcctggaaagccaacgggatcagaggaccatcagcatggccgagccaca 3456
|||||
Sbjct: 2250 gctgcagagcctcctggaaagccaacgggatcagaggaccatcagcatggccgagccaca 2191

Query: 3457 cagctcccaggagctctggatacaagctccccagggacccagcatccctttgccctgag 3516
|||||
Sbjct: 2190 cagctcccaggagctctggatacaagctccccagggacccagcatccctttgccctgag 2131

Query: 3517 acaccaatccctggagcatcctggagcatctcccctaccacccccggggggctgccttg 3576
|||||
Sbjct: 2130 acaccaatccctggagcatcctggagcatctcccctaccacccccggggggctgccttg 2071

Query: 3577 ggctggactcagacacctacgccagtccttgaggacaaagggcaacctggagaagacctg 3636
|||||
Sbjct: 2070 ggctggactcagacacctacgccagtccttgaggacaaagggcaacctggagaagacctg 2011

Query: 3637 agacatcccggcaccagcctcctgctgacctgcccg 3674
|||||
Sbjct: 2010 agacatcccggcaccagcctcctgctg-cctccccg 1974

Score = 262 bits (132), Expect = 1e-66
Identities = 133/134 (99%)
Strand = Plus / Minus

Query: 2935 cagtgcctctgccacctgtggagagggcatccagcagcggcaggtggtgtgcaggaccaac 2994

|||||
Sbjct: 4860 cagtgtctgtccacctgtggagagggcatccagcagcggcaggtggtgtgcaggaccaac 4801

Query: 2995 gccaacagcctcgggcattgcgagggggataggccagacactgtccaggtctgcarcctg 3054
|||||
Sbjct: 4800 gccaacagcctcgggcattgcgagggggataggccagacactgtccaggtctgcagcctg 4741

Query: 3055 cccgcctgtggagg 3068
|||||
Sbjct: 4740 cccgcctgtggagg 4727

Score = 254 bits (128), Expect = 2e-64
Identities = 128/128 (100%)
Strand = Plus / Minus

Query: 3179 tgtgtgcagcggagccctgcacgggagacaggtctgtcttctgccagatggaagtgtctg 3238
|||||
Sbjct: 2468 tgtgtgcagcggagccctgcacgggagacaggtctgtcttctgccagatggaagtgtctg 2409

Query: 3239 atcgctactgtccattcccgggtaccacgggtctgtgtgtgtcctgcacgaagaagg 3298
|||||
Sbjct: 2408 atcgctactgtccattcccgggtaccacgggtctgtgtgtgtcctgcacgaagaagg 2349

Query: 3299 cctcgggc 3306
|||||
Sbjct: 2348 cctcgggc 2341

Score = 221 bits (111), Expect = 4e-54
Identities = 112/113 (99%)
Strand = Plus / Minus

Query: 3066 aggaaatcaccagaactccacggtgagggccgatgtctgggaacttgggacgccagaggg 3125
|||||
Sbjct: 4646 aggaaatcaccagaactccacggtgagggccgatgtctgggaacttgggacgccagaggg 4587

Query: 3126 gcagtgggtgccacaatctgraccctacatcccattaacaagatatcatcaa 3178
|||||
Sbjct: 4586 gcagtgggtgccacaatctgaaccctacatcccattaacaagatatcatcaa 4534

Score = 145 bits (73), Expect = 2e-31
Identities = 73/73 (100%)
Strand = Plus / Minus

Query: 3687 gccctgccatcccactggcacgtttacactctgtgtactgccccgtgactcccagctcag 3746
|||||
Sbjct: 1960 gccctgccatcccactggcacgtttacactctgtgtactgccccgtgactcccagctcag 1901

Query: 3747 aggacacacatag 3759
|||||
Sbjct: 1900 aggacacacatag 1888

>AC007484.2.57778.65289
Length = 7512

Score = 387 bits (195), Expect = e-104
Identities = 195/195 (100%)
Strand = Plus / Minus

Query: 678 agcctttggcctgggagaccttcccaacctgctgggcctggtgggggaccagctgggcga 737
|||||
Sbjct: 2978 agcctttggcctgggagaccttcccaacctgctgggcctggtgggggaccagctgggcga 2919

Query: 738 cacagagcggaagcgggcgcatgccaaaggcaggcagctacagcatcgaggtgctgctggt 797
|||||
Sbjct: 2918 cacagagcggaagcgggcgcatgccaaaggcaggcagctacagcatcgaggtgctgctggt 2859

Query: 798 ggtggacgactcggtggttcgcttccatggcaaggagcatgtgcagaactatgtcctcac 857
|||||
Sbjct: 2858 ggtggacgactcggtggttcgcttccatggcaaggagcatgtgcagaactatgtcctcac 2799

Query: 858 cctcatgaatatcgt 872
|||||
Sbjct: 2798 cctcatgaatatcgt 2784

>AC007484.2.112555.124636
Length = 12082

Score = 314 bits (158), Expect = 3e-82
Identities = 158/158 (100%)
Strand = Plus / Plus

Query: 522 ggcgggcctcatccgcacagacagcaccgacttcttcattgagcctctggagcggggcca 581
|||||
Sbjct: 10474 ggcgggcctcatccgcacagacagcaccgacttcttcattgagcctctggagcggggcca 10533

Query: 582 gcaggagaaggaggccagcgaggagacacatgtggtgtaccgcccggaggccgtccagca 641
|||||
Sbjct: 10534 gcaggagaaggaggccagcgaggagacacatgtggtgtaccgcccggaggccgtccagca 10593

Query: 642 ggagtgggcagAACCTGACGGGGACCTGCACAATGAAG 679
|||||
Sbjct: 10594 ggagtgggcagAACCTGACGGGGACCTGCACAATGAAG 10631

>AC010216.8.1.110753
Length = 110753

Score = 139 bits (70), Expect = 1e-29
Identities = 101/112 (90%), Gaps = 4/112 (3%)
Strand = Plus / Plus

Query: 1490 ggacctttgagccctgcaagcagctgtggtgcagccatcctgacaaccmgtayttctgca 1549
|||||
Sbjct: 32976 ggacctttgacccctgcaagcagctgtggtgcagccatcctgacaacccctacttttgca 33035

Query: 1550 agaccaagaagggggcccccgcct-ggatgggactga-gtgtgcacccggcaag 1599
|||||
Sbjct: 33036 agaccaagaagggggccccc-cttggacgggact-atgtgtgcacctggcaag 33085

Score = 129 bits (65), Expect = 1e-26
Identities = 83/89 (93%)
Strand = Plus / Plus

Query: 1261 ctgggcagcgtcatggcgcccctggtgcaggctgccttcaccgcttccattggtcccg 1320
|||||
Sbjct: 31087 ctgggcagcatcatggcgcccctggtgcaggcgcttcaccgcttccactggtcccg 31146

Query: 1321 tgcagcaagctggagctcagccgctacct 1349
|||||
Sbjct: 31147 tgcagccagcaggagctgagccgctacct 31175